treprostinil
Selected indexed studies
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. (N Engl J Med, 2021) [PMID:33440084]
- Treprostinil Use in the NICU. (Adv Neonatal Care, 2024) [PMID:39602092]
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. (Lancet Respir Med, 2021) [PMID:34214475]
_Worker-drafted node — pending editorial review._
Connections
treprostinil is a side effect of
Sources
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (2010) pubmed
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. (2021) pubmed
- Treprostinil Use in the NICU. (2024) pubmed
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. (2021) pubmed
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. (2023) pubmed
- Treprostinil in the treatment of pulmonary arterial hypertension. (2020) pubmed
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. (2024) pubmed
- Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. (2020) pubmed
- Treprostinil sodium Pharmacia. (2002) pubmed
- Treprostinil for pulmonary hypertension. (2008) pubmed